MacroGenics Inc (NASDAQ:MGNX) Given Consensus Rating of “Buy” by Brokerages
MacroGenics Inc (NASDAQ:MGNX) has been assigned a consensus rating of “Buy” from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $30.98.
A number of research analysts recently commented on the company. Cowen restated a “buy” rating on shares of MacroGenics in a research note on Wednesday, June 5th. Stifel Nicolaus cut their target price on MacroGenics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Wedbush reiterated an “outperform” rating and set a $27.00 price objective on shares of MacroGenics in a research note on Thursday, July 18th. ValuEngine lowered MacroGenics from a “buy” rating to a “hold” rating in a research note on Monday, July 8th. Finally, Zacks Investment Research upgraded MacroGenics from a “hold” rating to a “buy” rating and set a $15.00 price objective for the company in a research note on Wednesday, August 7th.
Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace North America L.P. acquired a new position in MacroGenics during the first quarter worth $59,000. Pearl River Capital LLC acquired a new position in MacroGenics during the first quarter worth $74,000. Marshall Wace LLP acquired a new position in MacroGenics during the first quarter worth $80,000. Bank of Montreal Can raised its stake in MacroGenics by 804.2% during the first quarter. Bank of Montreal Can now owns 5,000 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 4,447 shares in the last quarter. Finally, Quantamental Technologies LLC acquired a new position in MacroGenics during the second quarter worth $122,000.
MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.31. The business had revenue of $10.59 million during the quarter, compared to analyst estimates of $17.58 million. MacroGenics had a negative return on equity of 54.52% and a negative net margin of 273.47%. Sell-side analysts forecast that MacroGenics will post -3.2 earnings per share for the current fiscal year.
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Read More: How to calculate compound interest
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.